The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.
SBC: NEUPHARMA, INC. Topic: CBD05116
The overall objective of this Phase II proposal is to determine the advantages of imidazenil over diazepam or midazolam as a potential anticonvulsant agent for the prophylaxis and for the emergency treatment of organophosphate nerve agent exposure. Therefore, we will compare the dose-dependent efficacy and anticonvulsant tolerance liability of imidazenil or midazolam for protecting rats against di ...SBIR Phase II 2007 Department of DefenseOffice for Chemical and Biological Defense
Development of a Database Management System to Enable Rapid, Efficient Assay Design for Use in Detection and Diagnosis of Human Exposure to BiologicalSBC: CFD Research Corporation Topic: CBD07114
The primary objective of this effort is to design and develop a database management system (DBMS) and enable the integrated interpretation of the vast amounts of genomic and proteomic data in proper biological context. This DBMS will enable the development of diagnostic assays for human exposure to specific biological threat agents using an existing suite of systems biology tools. The DBMS design ...SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
SBC: Rehabtek LLC Topic: N/A
Develops a low-cost and portable rehabilitation device with intelligent control to stretch spastic joints safely and repeatedly througout the range of motion to reduce spasticity/contracture and increase functional performanceSBIR Phase I 2007 Department of Education